Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients

Therapeutic Advances in Drug Safety

Volumn 4, Issue 6, 2013, Pages 235-245

  Bostock, Clare v ^a   Soiza, Roy l ^b   Mangoni, arduino a ^c  

^a WOODEND HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Aged; Anticholinergic Risk Scale; Barthel Index; cholinergic antagonists; Drug Burden Index; drug toxicity; frail elderly; muscarinic antagonists

Indexed keywords

AMITRIPTYLINE; CETIRIZINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CITALOPRAM; CYCLIZINE; DULOXETINE; ESCITALOPRAM; FEXOFENADINE; FLUOXETINE; HALOPERIDOL; HYDROXYZINE; IPRATROPIUM BROMIDE; LEVODOPA; LOFEPRAMINE; LORATADINE; MIRTAZAPINE; OXYBUTYNIN; PAROXETINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; SOLIFENACIN; TIOTROPIUM BROMIDE; TOLTERODINE; TRAZODONE; TRIFLUOPERAZINE; TROSPIUM CHLORIDE;

AGED; ARTICLE; BARTHEL INDEX; COGNITION; COMMUNITY LIVING; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FUNCTIONAL STATUS; GERIATRICS; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL TEST; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84898886834     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613500689     Document Type: Article

References (23)

1. Bostock C. Soiza R. Mangoni A. (2010) Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people. Expert Rev Clin Pharmacol 3: 441–452.
2. British Medical Association and Royal Pharmaceutical Society of Great Britain (2011) British National Formulary, 62nd edition. London: RPS Publishing.
3. Cao Y. Mager D. Simonsick E. Hilmer S. Ling S. Windham B. (2008) Physical and cognitive performances and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 83: 422–429.
4. Casarosa P. Keichle T. Sieger P. Pieper M. Ganter F. (2010) The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics. J Pharmacol Exp Ther 333: 201–209.
5. de Groot V. Beckerman H. Lankhorst G. Bouter L. (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56: 221–229.
6. Folstein M. Folstein S. McHugh P. (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.
7. Gnjidic D. Bell J. Hilmer S. Lönnroos E. Sulkava R. Hartikainen S. (2012a) Drug Burden Index associated with function in community-dwelling older people in Finland: A cross sectional study. Ann Med 44: 458–467.
8. Gnjidic D. Cumming R. Le Couteur D. Handelsman D. Naganathan V. Abernethy D. (2009) Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol 68: 97–105.
9. Gnjidic D. Le Couter D. Abernethy D. Hilmer S. (2012b) Drug Burden Index and Beers Criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol 52: 258–265.
10. Hall W. Ramachandran R. Narayan S. Jani A. Vijayakumer S. (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 4: 94.
11. Han L. Agostini J. Allore H. (2008) Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 56: 2203–2210.
12. Hilmer S. Mager D. Simonsick E. Cao Y. Ling S. Windham G. (2007) A Drug Burden Index to define the functional burden of medications in older people. Arch Intern Med 167: 781–787.
13. Hilmer S. Mager D.E. Simonsick E. Ling S. Windham B. Harris T. (2009) Drug Burden Index score and functional decline in older people. Am J Med 122: 1142–1149.
14. Hodkinson H. (1972) Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1: 233–238.
15. Lechevallier-Michel N. Molimard M. Dartidues J. Fabrigoule C. Fourrier-Reglat A. (2005) Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 59: 143–151.
16. Levey A. Coresh J. Greene T. Stevens L. Zhang Y. Hendriksen S. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254.
17. Lowry E. Woodman R. Soiza R. Mangoni A. (2011a) Associations between the Anticholinergic Risk Scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc 12: 565–572.
18. Lowry E. Woodman R. Soiza R. Mangoni A. (2011b) Clinical and demographic factors associated with antimuscarinic medication use in older hospitalised patients. Hosp Pract 39: 30–36.
19. Lowry E. Woodman R. Soiza R. Hilmer S. Mangoni A. (2012) Drug Burden Index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol 52: 1584–1591.
20. Mahoney F. Barthel D. (1965) Functional evaluation: the Barthel Index. Md State Med J 14: 61–65.
21. Mangoni A. (2011) Assessing the adverse effects of antimuscarinic drugs in older patients: which way forward? Exp Rev Clin Pharmacol 4: 531–533.
22. Rudolph J. Salow M. Angelini M. McGlinchey R. (2008) The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med 168: 508–513.
23. Wilson N. Hilmer S. March L. Cameron I. Lord S. Seibel M. (2011) Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 59: 875–880.